Loading
II
ImmunoGen, Inc. Stock: price and insider trades · United States
ImmunoGen, Inc.: what insiders have been doing
ImmunoGen, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Waltham, United States, founded in 1981. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for ImmunoGen, Inc. The previous disclosure was published on 12 February 2024.
Looking back to 2016, when coverage begins, insiders filed no purchases and 5 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
86
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€101,806
5 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$191.9M
Last declaration on 12 February 2024
Declarations86 total
103,000 sharesCommon StockSEC:0001104659-24-014721:0
60,720 sharesCommon StockSEC:0001104659-24-014708:0
1,327 sharesCommon StockSEC:0001104659-24-014692:0
1,000 sharesCommon StockSEC:0001104659-24-014696:0
73,274 sharesCommon StockSEC:0001104659-24-014711:0
3,074 sharesCommon StockSEC:0001104659-24-014717:0
10,000 sharesCommon StockSEC:0001104659-24-014714:0
5,381 sharesCommon StockSEC:0001104659-24-014706:0
584,397 sharesCommon StockSEC:0001104659-24-014715:0
21,039 sharesCommon StockSEC:0001104659-24-014705:0
14,723 sharesCommon StockSEC:0001104659-24-014710:0
8,435 shares0Common StockSEC:0001415889-24-002870:0
29,640 shares0Common StockSEC:0001415889-24-002872:0
51,234 shares0Common StockSEC:0001415889-24-002871:0
14,350 shares0Common StockSEC:0001415889-24-002873:0
58,900 shares@ US$4.8311.4% of flowCommon StockSEC:0001415889-24-001545:0
615 shares@ US$16.010.4% of flowCommon StockSEC:0001415889-24-000379:0
1,327 shares@ US$16.01100.0% of flowCommon StockSEC:0001415889-24-000380:0
442 shares@ US$29.6524.5% of flowCommon StockSEC:0001415889-24-000373:0
252 shares@ US$29.6524.4% of flowCommon StockSEC:0001415889-24-000372:0
467 shares@ US$16.012.6% of flowCommon StockSEC:0001415889-24-000378:0
30,000 shares@ US$5.3213.9% of flowCommon StockSEC:0001415889-24-000381:0
569 shares@ US$29.657.6% of flowCommon StockSEC:0001415889-24-000376:0
15,000 shares0Common StockSEC:0001415889-23-016970:0
27,788 shares@ US$4.555.0% of flowCommon StockSEC:0001415889-23-016754:0
25 of 86 declarations
About ImmunoGen, Inc.
ImmunoGen, Inc. was a U.S. biopharmaceutical company focused on antibody-drug conjugates (ADCs), a highly targeted cancer-therapy modality that combines antibody precision with potent cytotoxic payload delivery. Founded in Massachusetts in 1981, the company built its identity over decades around oncology research and development. Its headquarters were in Waltham, Massachusetts, United States, and its shares traded on the NASDAQ under the ticker IMGN prior to the acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000104746910007750/a2199944z10-k.htm?utm_source=openai))
Operationally, ImmunoGen concentrated on developing and commercializing ADC-based treatments for cancers with significant unmet medical need. Its flagship asset was ELAHERE (mirvetuximab soravtansine-gynx), an oncology therapy designed for patients with FRα-positive ovarian cancer. Beyond the lead product, the company also maintained a pipeline of next-generation ADC candidates, which gave ImmunoGen the profile of a technology platform company rather than a single-asset biotech. In market materials, ImmunoGen was described as a leader in the expanding field of ADCs for cancer treatment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000155837023007145/imgn-20230428xex99d1.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, ImmunoGen occupied a meaningful niche in the highly competitive oncology landscape, where large pharmaceutical groups and specialized ADC developers constantly vie for clinical differentiation, regulatory success, and commercial share. The company’s investment case was anchored in three elements: the clinical and commercial promise of ELAHERE, the credibility of its ADC platform, and the optionality embedded in follow-on pipeline assets. That combination gave ImmunoGen a reputation as a scientifically credible but mid-sized oncology platform with asymmetric upside if its lead program performed well. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855654/000155837023007145/imgn-20230428xex99d1.htm?utm_source=openai))
The most important recent corporate development was AbbVie’s acquisition of ImmunoGen. AbbVie announced the transaction in late 2023, valuing ImmunoGen at about $10.1 billion, and completed the acquisition on February 12, 2024. AbbVie said the deal would strengthen its solid-tumor oncology franchise and add ELAHERE plus ImmunoGen’s next-generation ADC pipeline to its broader portfolio. As a result, ImmunoGen is no longer an independent listed company, but its historic filings remain relevant for investors analyzing legacy SEC Form 4 insider transactions and the company’s pre-acquisition operating history. ([investors.abbvie.com](https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy?utm_source=openai))
In short, ImmunoGen was a precision-oncology biotech with a high-risk/high-reward profile, centered on ADC science and a commercially important lead asset. For French-speaking investors, it is also a good example of how innovative U.S. biotech companies listed on NASDAQ in the United States are often consolidated by larger pharmaceutical players once a lead product proves its strategic value. ([investors.abbvie.com](https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
